**Contents**

### Highlights of This Issue  1049

#### REVIEWS

- **1051**  
  **Attacking a Nexus of the Oncogenic Circuitry by Reversing Aberrant eIF4F-Mediated Translation**  
  Peter B. Bitterman and Vitaly A. Polunovsky

- **1062**  
  **Immunotherapy of Cancer with 4-1BB**  
  Dass S. Vinay and Byoung S. Kwon

### THERAPEUTIC DISCOVERY

- **1071**  
  **Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition**  

- **1082**  
  **Hyperactivation of 4E-Binding Protein 1 as a Mediator of Biguanide-Induced Cytotoxicity during Glucose Deprivation**  
  Junichi Matsuo, Yoshinori Tsukumo, Sakae Saito, Satomi Tsukahara, Junko Sakurai, Shigeo Sato, Hiromichi Kondo, Masaru Ushijima, Masaaki Matsuura, Toshiki Watanabe, and Akihiro Tomida

- **1092**  
  **Off-Target Function of the Sonic Hedgehog Inhibitor Cyclopamine in Mediating Apoptosis via Nitric Oxide–Dependent Neutral Sphingomyelinase 2/Ceramide Induction**  

### PRECLINICAL DEVELOPMENT

- **1103**  
  **Evading Pgp Activity in Drug-Resistant Cancer Cells: A Structural and Functional Study of Antitubulin Furan Metotica Compounds**  
  Tam Luong Nguyen, Maria Rosaria Cera, Andrea Pinto, Leonardo Lo Presti, Ernest Hamel, Paola Conti, Rick Gussio, and Peter De Wulf

- **1112**  
  **JAK–STAT and JAK–PI3K–mTORC1 Pathways Regulate Telomerase Transcriptionally and Posttranslationally in ATL Cells**  
  Osamu Yamada, Kohji Ozaki, Masaharu Akiyama, and Kiyotaka Kawauchi

- **1122**  
  **Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo**  
  Girija Dasmahapatra, Dmitry Lembersky, Minkyeong P. Son, Hiral Patel, Richard Peterson, Elisa Attiksson, Paul Dent, and Steven Grant

- **1133**  
  **The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates**  
  Hans K. Erickson, Gail D. Lewis, Douglas D. Leipold, Carmela A. Provenzano, Elaine Mai, Holly A. Johnson, Bert Gunter, Charlene A. Audee, Manish Gupta, Jan Pinkas, and Jay Tibbitts

- **1143**  
  **ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors**  
  Georgia Hatzivassiliou, Bonnie Liu, Carol O’Brien, Jii M. Spoelke, Klaus P. Hoeflich, Peter M. Haverty, Robert Soriano, William F. Forrest, Sherry Heldens, Huifen Chen, Karen Toy, Connie Ha, Wei Zhou, Kyung Song, Lori S. Friedman, Lukas C. Amler, Garret M. Hampton, John Moffat, Mark R. Lackner

- **1155**  
  **Triggering Fbw7-Mediated Proteasomal Degradation of c-Myc by Oridonin Induces Cell Growth Inhibition and Apoptosis**  
  Hui-Lin Huang, Heng-You Weng, Lu-Qin Wang, Chun-Hong Yu, Qiao-Juan Huang, Pan-Pan Zhao, Jun-Zhi Wen, Hui Zhou, and Liang-Hu Qu
miRNA-29b Suppresses Prostate Cancer Metastasis by Regulating Epithelial–Mesenchymal Transition Signaling

Peng Ru, Robert Steele, Philip Newhall, Nancy J. Phillips, Karoly Toth, and Ratna B. Ray

1174

Therapeutic Significance of Estrogen Receptor β Agonists in Gliomas

Gangadhara R. Sareddy, Binoj C. Nair, Vijay K. Gonugunta, Quan-guang Zhang, Andrew Brenner, Darrell W. Brann, Rajeshwar Rao Tekmal, and Ratna K. Vadlamudi

1183

Multiple Antigenic Peptides Based on H-2K<sup>b</sup>-Restricted CTL Epitopes from Murine Heparanase Induce a Potent Antitumor Immune Response In Vivo

Xu-Dong Tang, Guo-Zhen Wang, Jun Guo, Mu-Han Li, Chuan Li, Ning Li, Ya-Ling Chao, Chang-Zhu Li, Yu-Yun Wu, Chang-Jiang Hu, Dian-Chun Fang, and Shi-Ming Yang

RETraction

1214

Retraction in Part: A Genomic Approach to Identify Molecular Pathways Associated with Chemotherapy Resistance

CorRection

1216

Correction: Narciclasine, a Plant Growth Modulator, Activates Rho and Stress Fibers in Glioblastoma Cells

ABOUT THE COVER

Several allosteric MEK inhibitors are in clinical development and have been designed to treat patients with tumors harboring RAS/RAF pathway alterations. Acquired resistance to this class of inhibitors is a pressing clinical problem. To identify strategies to overcome this resistance, Hatzivassiliou and colleagues derived and characterized three independent MEK inhibitor-resistant cell lines. All of the resistant cell lines harbored mutations in the allosteric binding pocket of MEK that is targeted by arylamine MEK inhibitors. In all cases the MEK resistant cell lines retained their addiction to the MAPK pathway and remained sensitive to a selective inhibitor of the ERK1/2 kinases, suggesting a role for ERK inhibitors in combating or preventing MEK inhibitor resistance. For details, see article by Hatzivassiliou and colleagues on page 1143.